Binding of fusion protein FLSC IgG1 to CCR5 is enhanced by CCR5 antagonist Maraviroc

被引:5
作者
Latinovic, Olga [1 ,2 ]
Schneider, Kate [1 ,2 ]
Szmacinski, Henryk [3 ]
Lakowicz, Joseph R. [3 ]
Heredia, Alonso [1 ,4 ]
Redfield, Robert R. [1 ,4 ]
机构
[1] Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD 21201 USA
[2] Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA
[3] Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA
[4] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA
关键词
HIV-1; CCR5; antagonist; Maraviroc; Fusion protein; HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-1; CHEMOKINE; TYPE-1; EXPRESSION; ENTRY; ANTIBODY; CELLS; CD4; INFECTIONS;
D O I
10.1016/j.antiviral.2014.10.006
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The CCR5 chemokine receptor is crucial for human immunodeficiency virus type 1 (HIV-1) infection, acting as the principal coreceptor for HIV-1 entry and transmission and is thus an attractive target for antiviral therapy. Studies have suggested that CCR5 surface density and its conformational changes subsequent to virion engagement are rate limiting for entry, and consequently, infection. Not all CCR5 antibodies inhibit HIV-1 infection, suggesting a need for more potent reagents. Here we evaluated full length single chain (FLSC) IgG1, a novel IgG-CD4-gp12(BAL) fusion protein with several characteristics that make it an attractive candidate for treatment of HIV-1 infections, including bivalency and a potentially increased serum half-life over FLSC, the parental molecule. FLSC IgG1 binds two domains on CCR5, the N-terminus and the second extracellular loop, lowering the levels of available CCR5 viral attachment sites. Furthermore, FLSC IgG1 synergizes with Maraviroc (MVC), the only licensed CCR5 antagonist. In this study, we used both microscopy and functional assays to address the mechanistic aspects of the interactions of FLSC IgG1 and MVC in the context of CCR5 conformational changes and viral infection. We used a novel stochastic optical reconstruction microscopy (STORM), based on high resolution localization of photoswitchable dyes to visualize direct contacts between FLSC IgG1 and CCR5. We compared viral entry inhibition by FLSC IgG1 with that of other CCR5 blockers and showed FLSC IgG1 to be the most potent. We also showed that lower CCR5 surface densities in HIV-1 infected primary cells result in lower FLSC IgG1 EC50 values. In addition, CCR5 binding by FLSC IgG1, but not CCR5 Ab 2D7, was significantly increased when cells were treated with MVC, suggesting MVC allosterically increases exposure of the FLSC IgG1 binding site. These data have implications for future antiviral therapy development. (C) 2014 Elsevier B.V. All rights reserved.
引用
收藏
页码:80 / 90
页数:11
相关论文
共 50 条
[41]   CCR5 Antagonist Blocks Metastasis of Basal Breast Cancer Cells [J].
Velasco-Velazquez, Marco ;
Jiao, Xuanmao ;
De la Fuente, Marisol ;
Pestell, Timothy G. ;
Ertel, Adam ;
Lisanti, Michael P. ;
Pestell, Richard G. .
CANCER RESEARCH, 2012, 72 (15) :3839-3850
[42]   CCR1 and CCR5 promote hepatic fibrosis in mice [J].
Seki, Ekihiro ;
De Minicis, Samuele ;
Gwak, Geum-Youn ;
Kluwe, Johannes ;
Inokuchi, Sayaka ;
Bursill, Christina A. ;
Llovet, Josep M. ;
Brenner, David A. ;
Schwabe, Robert F. .
JOURNAL OF CLINICAL INVESTIGATION, 2009, 119 (07) :1858-1870
[43]   Synergistic Inhibition of R5 HIV-1 by the Fusion Protein (FLSC) IgG1 Fc and Maraviroc in Primary Cells: Implications for Prevention and Treatment [J].
Latinovic, Olga S. ;
Zhang, Jian ;
Tagaya, Yutaka ;
DeVico, Anthony L. ;
Fouts, Timothy R. ;
Schneider, K. ;
Lakowicz, Joseph R. ;
Heredia, Alonso ;
Redfield, Robert R. .
CURRENT HIV RESEARCH, 2016, 14 (01) :24-36
[44]   A dual CCR2/CCR5 chemokine antagonist, BMS-813160? [J].
Norman, Peter .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2011, 21 (12) :1919-1924
[45]   Discovery of a Potent and Orally Bioavailable CCR2 and CCR5 Dual Antagonist [J].
Pasternak, Alexander ;
Goble, Stephen D. ;
Struthers, Mary ;
Vicario, Pasquale P. ;
Ayala, Julia M. ;
Di Salvo, Jerry ;
Kilburn, Ruth ;
Wisniewski, Thomas ;
DeMartino, Julie A. ;
Mills, Sander G. ;
Yang, Lihu .
ACS MEDICINAL CHEMISTRY LETTERS, 2010, 1 (01) :14-18
[46]   In vitro effects of the CCR5 inhibitor maraviroc on human T cell function [J].
Arberas, H. ;
Guardo, A. C. ;
Bargallo, M. E. ;
Maleno, M. J. ;
Calvo, M. ;
Blanco, J. L. ;
Garcia, F. ;
Gatell, J. M. ;
Plana, M. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2013, 68 (03) :577-586
[47]   NMR Analyses of the Interaction between CCR5 and Its Ligand Using Functional Reconstitution of CCR5 in Lipid Bilayers [J].
Yoshiura, Chie ;
Kofuku, Yutaka ;
Ueda, Takumi ;
Mase, Yoko ;
Yokogawa, Mariko ;
Osawa, Masanori ;
Terashima, Yuya ;
Matsushima, Kouji ;
Shimada, Ichio .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2010, 132 (19) :6768-6777
[48]   Editorial: CCR5: A receptor at the center stage in infection [J].
Ellwanger, Joel Henrique ;
Secchi, Massimiliano ;
Aliberti, Julio ;
Vangelista, Luca .
FRONTIERS IN IMMUNOLOGY, 2022, 13
[49]   CCR5 blockage by maraviroc: a potential therapeutic option for metastatic breast cancer [J].
Asim Pervaiz ;
Michael Zepp ;
Saqib Mahmood ;
Doaa Mohamed Ali ;
Martin R. Berger ;
Hassan Adwan .
Cellular Oncology, 2019, 42 :93-106
[50]   CCR5 as a Treatment Target in Pulmonary Arterial Hypertension [J].
Amsellem, Valerie ;
Lipskaia, Larissa ;
Abid, Shariq ;
Poupel, Lucie ;
Houssaini, Amal ;
Quarck, Rozenn ;
Marcos, Elisabeth ;
Mouraret, Nathalie ;
Parpaleix, Aurelien ;
Bobe, Regis ;
Gary-Bobo, Guillaume ;
Saker, Mirna ;
Dubois-Rande, Jean-Luc ;
Gladwin, Mark T. ;
Norris, Karen A. ;
Delcroix, Marion ;
Combadiere, Christophe ;
Adnot, Serge .
CIRCULATION, 2014, 130 (11) :880-+